Spotlight
Specialty
Partners
CME/CE
The ZUMA-3 Trial: Clinical Endpoints
Thought leaders in the management of ALL discuss the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy, and lead trial author Bijal Shah, MD, MS, comments on the future application of MRD status.
EP: 1.The Evolving Treatment Landscape for ALL
EP: 2.Using MRD to Monitor Therapeutic Response in ALL
EP: 3.The ZUMA-3 Trial: Study Design and Patient Population
EP: 4.The ZUMA-3 Trial: Efficacy and Safety Results
Now Viewing
EP: 5.The ZUMA-3 Trial: Clinical Endpoints
EP: 6.The Potential Future Impact of CAR T Cell Therapy in Adult ALL
Related Videos
Related Content
